DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

ATLANTA and LA JOLLA, Calif., Dec. 15, 2021 /PRNewswire/ -- BioIQ, Inc., ("BioIQ") an analytics-driven population health and testing platform company for top employers, health plans, and government agencies, and DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement to bring increased patient access to precision genomics.

BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solution Lineup

ARK Innovation ETF

Becton, Dickinson and Co.

Colgate-Palmolive

DocuSign

Upstart Holdings

We review 5 top stock ideas that have been created by the Fed's tomfoolery (3 are pure-growth stocks and 2 are dividend-growth stocks). We also discuss a big reason why cryptocurrency popularity continues to grow (hint: more Fed tomfoolery).

Fed Tomfoolery: 5 Top Stocks - 3 Pure-Growth, 2 Dividend-Growth

Skin-cancer detection could lead to big returns for this stock.

Why DermTech Still Has Ten-Bagger Potential

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the expansion and branding of its translational medicine service offering, DermTech Stratum™, which utilizes DermTech's non-invasive technology and precision biomarker approaches to bring heightened precision and personalization to dermatologic disease diagnosis and treatment development. This broadene

DermTech Unveils DermTech Stratum, an Expanded Translational Medicine Service Offering for Non-invasive Biomarker Analysis

Nothing major changed for the skin genomics company in Q3.

This Is the Main Problem With DermTech's Q3 Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its session presentation, focused on non-invasive precision dermatology approaches, at the fifth annual Dermatology Drug Development Summit for Inflammatory Skin Diseases. Held in Boston this year, the Dermatology Drug Development Summit is a prestigious forum committed to overcoming significant R&D hurdles and sha

DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit

FIGS

Pinterest

These stocks have grown quarterly sales 34%, 43%, and 140% year over year.

Got $50? 3 Roughed-Up Growth Stocks Set to Soar

10X Genomics

Both companies offer disruptive new solutions in their niches of the healthcare space.

Better Buy: 10x Genomics vs. DermTech

DermTech, Inc. (DMTK) CEO John Dobak on Q3 2021 Results - Earnings Call Transcript

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.62% and -10.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q3 Loss, Lags Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results for the quarter ended September 30, 2021. Third Quarter 2021 Highlights Billable sample volume of approximately 11,720 for the third quarter of 2021, a 75% increase compared to approximately 6,700 recorded for the third quarter of 2020 and flat sequentially compared to the second quarter of 2

DermTech Reports Third Quarter 2021 Financial Results

LA JOLLA, Calif. & PITTSBURGH--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, and DermatologistOnCall, a leading dermatology telehealth provider in the U.S., announced today an agreement to make the DermTech Melanoma Test available through DermatologistOnCall's telemedicine platform. The millions of patients served through DermatologistOnCall will now have increased access to DermT

DermTech and DermatologistOnCall Enter Agreement to Improve Access to the DermTech Melanoma Test with Noninvasive, At-Home Sample Collection

Easterly Government Properties

Their market caps are small, but their opportunities are big.

3 Top Small-Cap Stocks to Buy Right Now

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate DermTech, Inc. (DMTK) to Report a Decline in Earnings: What to Look Out for

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its third quarter 2021 financial results after the market closes on Tuesday, November 9, 2021. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and recent highlights.

DermTech to Announce Third Quarter Financial Results on November 9, 2021

Trupanion

You might not be familiar with these stocks. But you'll probably want to be.

These 3 Under-the-Radar Stocks Are Great Buys Right Now

These three facts can help you determine whether you want in on this fast-growing company.

3 Things About DermTech That Smart Investors Know

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the Company's participation in the inaugural Alliance for Innovation in Integrated Healthcare's Summit & Educational Program. The hybrid event featured a series of presentations by key leaders in payer, provider, pharmaceutical, legal, government and other healthcare sectors, who discussed their in

DermTech Presents in Expert Panel at Inaugural Alliance for Innovation in Integrated Healthcare Summit

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Nathalie Gerschtein Keraudy, President of the Consumer Products Division of L'Oréal, to its board of directors. “Nathalie has tremendous experience in building brands that consumers, clinicians, and the world recognize and trust,” said Matt Posard, the Chairman of DermTech's board of directors. “Her

DermTech Announces New Appointment of L'Oréal USA Leader Nathalie Gerschtein Keraudy to its Board of Directors

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open, an ATP 250 tournament, and a partnership with San Diego native and tennis pro Brandon Nakashima. The sponsorships further represent DermTech's commitment to the San Diego community and goal of raising awareness on the importance of sun safety and skin checks to ai

DermTech Sponsors San Diego Open; Partners with Tennis Pro Brandon Nakashima to Raise Awareness for Sun Safety

Innovative Industrial Properties

Matterport

These stocks have what it takes to deliver 100% returns in five years or less.

3 Stocks That Could Double Your Money Sooner Than You Think

DermTech, Inc. has developed an innovative, non-invasive test to diagnose skin cancer and other conditions.

DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics

DermTech's innovative skin treatment is making it easier and cheaper to test for skin cancer, causing the business to grow. Fast.

How DermTech Could Change Skin Cancer Testing -- Or Fizzle Out

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The Journal Of Cutaneous Medicine has published research including the results of DermTech's TRUST study. The large research study supports that evaluation of genomic atypia with DermTech's Pigmented Lesion Assay (“PLA” or the “DermTech Melanoma Test”) increases both the real-world negative predictive value

DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine

News for DermTech Inc Stock (DMTK)